BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway

Desensitization of hepatocellular carcinoma (HCC) to paclitaxel chemotherapy is a major deterrent to successful treatment of the cancer. Abnormal activation of the PI3K/Akt/mTOR, pathway is a common outcome of chemotherapy for HCC. Therefore, we investigated whether BEZ235, a dual PI3K and mTOR inhi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Transl Res
Autors principals: Liu, Xueke, Xie, Chunmei, Li, Amin, Zhang, Yinci, Liu, Xinkuang, Zhou, Shuping, Shen, Jing, Huo, Zhen, Cao, Weiya, Ma, Yongfang, Xu, Ruyue, Xing, Yingru, Xie, Yinghai, Cai, Shuyu, Tang, Xiaolong
Format: Artigo
Idioma:Inglês
Publicat: e-Century Publishing Corporation 2019
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6943462/
https://ncbi.nlm.nih.gov/pubmed/31934276
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars